Arcutis Biotherapeutics Inc’s recent filing unveils that its Director Heron Patrick J acquired Company’s shares for reported $25177.0 on Jun 04 ’25. In the deal valued at $13.32 per share,1,890 shares were bought. As a result of this transaction, Heron Patrick J now holds 24,424 shares worth roughly $0.33 million.
Then, Heron Patrick J bought 378 shares, generating $5,069 in total proceeds. Upon buying the shares at $13.41, the Director now owns 24,802 shares.
Before that, Matsuda Masaru sold 1,800 shares. Arcutis Biotherapeutics Inc shares valued at $24,807 were divested by the insider at a price of $13.78 per share. As a result of the transaction, Matsuda Masaru now holds 202,599 shares, worth roughly $2.71 million.
H.C. Wainwright initiated its Arcutis Biotherapeutics Inc [ARQT] rating to a Buy in a research note published on December 30, 2024; the price target was $19. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Mizuho also remained covering ARQT and has increased its forecast on January 03, 2024 with a “Buy” recommendation from previously “Neutral” rating. Mizuho revised its rating on October 26, 2023. It rated ARQT as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ARQT
On Monday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock fall -0.22% to $13.40. Over the last five days, the stock has lost -5.70%. Arcutis Biotherapeutics Inc shares have fallen nearly -3.80% since the year began. Nevertheless, the stocks have risen 65.43% over the past one year. While a 52-week high of $17.75 was reached on 03/25/25, a 52-week low of $7.64 was recorded on 02/11/25.
Levels Of Support And Resistance For ARQT Stock
The 24-hour chart illustrates a support level at 13.03, which if violated will result in even more drops to 12.65. On the upside, there is a resistance level at 13.81. A further resistance level may holdings at 14.21.
